miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 14, 2026

AI spending boom is boosting profits now, but could pressure Big Tech returns later: Goldman Sachs

View original at seekingalpha.com
AI spending boom is boosting profits now, but could pressure Big Tech returns later: Goldman Sachs [Server room] gremlin The artificial intelligence investment boom has helped propel S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]) profitability to record levels, but Goldman Sachs warns that the same spending wa…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Semiconductor net profit margins are approaching 50%, supported by pricing power and strong competitive positions

    60% confidence
  • Depreciation and amortization expenses for hyperscalers will rise from 7% of revenue in 2022 to 12% by 2027

    60% confidence
  • Consensus forecasts imply that return on equity for the largest technology companies will decline by an average of seven percentage points next year

    60% confidence
  • Every one percentage point change in S&P 500 ROE is associated with roughly a one-turn change in the market's P/E multiple

    60% confidence
  • More than half of S&P 500 companies discussed AI-related productivity initiatives during recent earnings calls, though relatively few have yet quantified the financial impact

    60% confidence
  • Improving revenue estimates, growing customer backlogs and expanding margins among major cloud providers are evidence that AI investments are beginning to generate returns

    60% confidence
  • The S&P 500 has returned 9% year-to-date despite a decline in valuation multiples, with consensus forward 12-month earnings estimates rising 17% while the P/E ratio contracted from 22x to 21x

    60% confidence
  • Record corporate profitability has become a key pillar supporting elevated U.S. stock valuations

    60% confidence
  • Apple is expected to experience the sharpest ROE drop next year, followed by Nvidia, Alphabet and Meta

    60% confidence
  • The broader productivity benefits of AI could ultimately offset near-term headwinds from AI infrastructure spending on Big Tech profitability

    60% confidence
  • Economics for AI models are expected to improve as computing costs per token decline while pricing stabilizes

    60% confidence
  • The seven largest technology stocks collectively generate a 44% return on equity, up nine percentage points over the past three years

    60% confidence
  • AI adoption will eventually increase revenue and earnings per employee across corporate America

    60% confidence
  • Major cloud operators will spend roughly $770 billion on capital expenditures in 2026, equivalent to about 100% of their operating cash flow

    60% confidence
  • The S&P 500 currently trades at about 21 times forward earnings, a level that ranks in the 87th percentile since 1980, while return on equity has climbed to a record 22%

    60% confidence

Data points we hold from this source

S&P 500 Index Fund · margin22 percent_ROE
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
AI spending boom is boosting profits now, but could pressure Big Tech returns later: Goldman Sachs — Source | Via News | es.VIA.NEWS